Longitudinal ctDNA monitoring has also identified NF1 mutations to be indicative of trastuzumab resistance; similarly, ctDNA-detectable MET amplifications underlie acquired resistance to the tyrosine kinase inhibitor afatinib in patients with HER2-positive gastric cancers [34]. The gene discussed is ERBB2; the disease is gastric cancer.